Stocks and Investing Stocks and Investing
Tue, March 21, 2023

Raghuram Selvaraju Maintained (BTAI) at Strong Buy with Decreased Target to $66 on, Mar 21st, 2023


Published on 2024-10-28 02:21:21 - WOPRAI, Raghuram Selvaraju
  Print publication without navigation


Raghuram Selvaraju of HC Wainwright & Co., Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $79 to $66 on, Mar 21st, 2023.

Raghuram has made no other calls on BTAI in the last 4 months.



There are 3 other peers that have a rating on BTAI. Out of the 3 peers that are also analyzing BTAI, 2 agree with Raghuram's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Chris Howerton of "Jefferies" Downgraded from Strong Buy to Hold and Increased Target to $22 on, Friday, March 10th, 2023
  • Corinne Jenkins of "Goldman Sachs" Maintained at Hold with Increased Target to $26 on, Thursday, January 26th, 2023


This is the rating of the analyst that currently disagrees with Raghuram


  • Graig Suvannavejh of "Mizuho" Maintained at Strong Buy with Increased Target to $38 on, Wednesday, February 8th, 2023
Contributing Sources